APPB: AI 评分 39/100 — AI 分析 (4月 2026)
Applied Biosciences Corp. develops and commercializes synthetic cannabinoid therapeutics and THC-free CBD products. The company also provides testing and analytics services.
Key Facts:
AI Score: 39/100
Sector: Healthcare
公司概况
概要：
Applied Biosciences Corp. develops and commercializes synthetic cannabinoid therapeutics and THC-free CBD products. The company also provides testing and analytics services.
Applied Biosciences Corp. focuses on synthetic cannabinoid therapeutics and THC-free CBD products, targeting the endocannabinoid system. Operating in the specialty and generic drug manufacturing sector, the company provides testing and analytics services, distinguishing itself through a vertically integrated approach from development to consumer products, despite its current financial challenges.
APPB是做什么的？
Applied Biosciences Corp., incorporated in 2014 and based in Beverly Hills, California, is a biopharmaceutical company focused on the development and commercialization of synthetic cannabinoid therapeutics. These therapeutics target the endocannabinoid system, aiming to treat a variety of diseases across multiple therapeutic areas. In addition to its pharmaceutical development efforts, Applied Biosciences delivers consumer and OTC THC-free CBD products designed to promote overall health and wellbeing. The company also offers testing and analytics capabilities to its customers, providing a comprehensive suite of services within the cannabinoid market.
Since its founding, Applied Biosciences has positioned itself as an innovator in the cannabinoid space, seeking to leverage the therapeutic potential of both synthetic cannabinoids and CBD. The company's strategy involves a vertically integrated approach, encompassing drug development, consumer product formulation, and analytical services. This allows Applied Biosciences to capture value across the entire cannabinoid value chain, from research and development to direct-to-consumer sales. Despite its innovative approach, the company faces challenges common to early-stage biopharmaceutical companies, including the need for significant capital investment and the complexities of regulatory approval processes.
APPB的投资论点是什么？
Applied Biosciences Corp. presents a high-risk, high-reward investment opportunity within the cannabinoid therapeutics and consumer CBD market. The company's focus on synthetic cannabinoids offers potential for novel treatments targeting the endocannabinoid system. However, its negative profit margin of -865.3% and gross margin of -358.5% indicate significant financial challenges. Future growth hinges on successful drug development, regulatory approvals, and market acceptance of its CBD products. The company's high beta of 732.83 suggests extreme volatility, making it suitable only for investors with a high-risk tolerance. Investment is contingent on the company securing additional funding and demonstrating progress in its clinical programs.
APPB在哪个行业运营？
Applied Biosciences Corp. operates in the rapidly evolving cannabinoid market, which includes both pharmaceutical and consumer segments. The industry is characterized by increasing research into the therapeutic potential of cannabinoids, growing consumer demand for CBD products, and evolving regulatory landscapes. Competition includes established pharmaceutical companies, specialized cannabinoid biotechs, and numerous CBD consumer brands. Applied Biosciences aims to differentiate itself through its focus on synthetic cannabinoids and its integrated approach, but it faces challenges from larger, better-funded competitors and the uncertainties of regulatory approval.
Drug Manufacturers - Specialty & Generic
Healthcare
APPB有哪些增长机遇？
- Expansion of Synthetic Cannabinoid Therapeutics: Applied Biosciences has the opportunity to develop and commercialize novel synthetic cannabinoid therapeutics targeting specific diseases. The global pharmaceutical market is multi-billion dollar, offering significant revenue potential for successful drug candidates. This opportunity depends on positive clinical trial results and regulatory approvals, with a timeline of several years for drug development and commercialization.
- Growth in the CBD Consumer Market: The market for CBD consumer products is experiencing rapid growth, driven by increasing consumer awareness and acceptance. Applied Biosciences can capitalize on this trend by expanding its range of THC-free CBD products and distribution channels. The global CBD market is projected to reach billions of dollars by 2030, presenting a substantial growth opportunity. Success depends on effective marketing, product innovation, and compliance with evolving regulations.
- Strategic Partnerships and Collaborations: Applied Biosciences can accelerate its growth by forming strategic partnerships with other companies in the pharmaceutical, biotechnology, and consumer product sectors. Collaborations can provide access to new technologies, markets, and funding sources. This strategy can reduce risk and accelerate the development and commercialization of its products. The timeline for realizing this opportunity depends on identifying suitable partners and negotiating mutually beneficial agreements.
- Development of Novel Drug Delivery Systems: Applied Biosciences can enhance the efficacy and patient experience of its cannabinoid therapeutics by developing novel drug delivery systems. This can include formulations for improved bioavailability, targeted delivery to specific tissues, and convenient routes of administration. The market for advanced drug delivery technologies is growing, driven by the demand for more effective and patient-friendly therapies. Success depends on innovation in formulation science and engineering.
- Expansion of Testing and Analytics Services: Applied Biosciences can leverage its testing and analytics capabilities to serve the growing demand for quality control and regulatory compliance in the cannabinoid industry. This includes providing testing services for other companies' products, as well as developing analytical tools for research and development. The market for cannabis testing services is expanding rapidly, driven by increasing regulation and consumer demand for product safety and transparency. Success depends on maintaining high standards of accuracy and reliability.
- Focus on synthetic cannabinoid therapeutics targeting the endocannabinoid system.
- Offers a range of THC-free CBD products for consumer use.
- Provides testing and analytics services to customers in the cannabinoid market.
- Incorporated in 2014, indicating a relatively young company in the biopharmaceutical sector.
- Based in Beverly Hills, California, a hub for the health and wellness industry.
APPB提供哪些产品和服务？
- Develops synthetic cannabinoid therapeutics.
- Commercializes synthetic cannabinoid therapeutics.
- Creates THC-free CBD products for consumer use.
- Sells THC-free CBD products for consumer use.
- Provides testing services for cannabinoid products.
- Provides analytics services for cannabinoid products.
APPB如何赚钱？
- Develops and patents synthetic cannabinoid formulations.
- Manufactures and distributes THC-free CBD products directly to consumers and through retail channels.
- Generates revenue through the sale of CBD products.
- Offers testing and analytics services to other companies in the cannabinoid industry.
- Consumers seeking THC-free CBD products for health and wellness.
- Patients who may benefit from synthetic cannabinoid therapeutics.
- Other companies in the cannabinoid industry requiring testing and analytics services.
- Proprietary synthetic cannabinoid formulations.
- Vertically integrated business model, encompassing drug development, consumer products, and analytical services.
- Expertise in targeting the endocannabinoid system.
- Established brand recognition in the THC-free CBD market.
什么因素可能推动APPB股价上涨？
- Upcoming: Potential regulatory approvals for synthetic cannabinoid therapeutics.
- Ongoing: Expansion of the company's THC-free CBD product line.
- Ongoing: Increasing consumer awareness and acceptance of CBD products.
APPB的主要风险是什么？
- Potential: Stringent regulatory requirements for cannabinoid-based products.
- Ongoing: Competition from larger, more established companies.
- Potential: Adverse effects or safety concerns associated with cannabinoid products.
- Ongoing: The company's financial instability, as indicated by negative profit and gross margins.
- Potential: Dependence on key personnel and the ability to attract and retain talent.
APPB的核心优势是什么？
- Focus on synthetic cannabinoids offers potential for novel therapeutics.
- Offers a range of THC-free CBD products for consumer use.
- Provides testing and analytics services, creating additional revenue streams.
- Vertically integrated business model allows for greater control over the supply chain.
APPB的劣势是什么？
- Negative profit and gross margins indicate financial instability.
- High beta suggests extreme stock price volatility.
- Limited information available regarding specific products in development.
- Small number of employees (25) may limit operational capacity.
APPB有哪些机遇？
- Expanding the range of synthetic cannabinoid therapeutics through research and development.
- Increasing market share in the growing CBD consumer market.
- Forming strategic partnerships to expand reach and resources.
- Capitalizing on the increasing demand for cannabinoid testing and analytics services.
APPB面临哪些威胁？
- Stringent regulatory requirements for cannabinoid-based products.
- Competition from larger, more established pharmaceutical and consumer product companies.
- Changing consumer preferences and market trends.
- Potential for adverse effects or safety concerns associated with cannabinoid products.
APPB的竞争对手是谁？
- Alkaloid, AD — Pharmaceutical company with a diverse product portfolio. — (ALID)
- BioAdaptives, Inc. — Focuses on adaptogenic and immunomodulatory products. — (BINP)
- Planet Green Holdings Corp. — CBD product manufacturer and distributor. — (CBDY)
- CANNA-PET Advanced Pet Products, Inc. — Specializes in CBD products for pets. — (CNNA)
- COMPUMED, Inc. — Healthcare technology and services provider. — (CPMD)
Key Metrics
- MoonshotScore: 39/100
Company Profile
- CEO: Christopher Michael Bridges
- Headquarters: Beverly Hills, US
- Employees: 25
- Founded: 2016
AI Insight
AI analysis pending for APPB
- OTC Tier: OTC Other
- Disclosure Status: Unknown
常见问题
What does Applied Biosciences Corp. do?
Applied Biosciences Corp. is a biopharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics that target the endocannabinoid system. The company also delivers consumer and OTC THC-free CBD products that promote overall health and wellbeing. In addition, Applied Biosciences provides testing and analytics capabilities to its customers. The company aims to capitalize on the growing interest in cannabinoid-based products and therapies, addressing both the pharmaceutical and consumer markets.
What do analysts say about APPB stock?
There is no available analyst coverage for Applied Biosciences Corp. (APPB). The company's OTC listing and limited financial information may deter analyst coverage. Investors should conduct their own thorough research and due diligence before investing in APPB, considering the lack of external analysis and the inherent risks associated with OTC stocks. Key valuation metrics such as P/E ratio are currently not meaningful due to negative earnings.
What are the main risks for APPB?
Applied Biosciences Corp. faces several significant risks. The company's negative profit and gross margins indicate financial instability and raise concerns about its ability to sustain operations. As an OTC-listed company with limited disclosure, APPB is subject to higher regulatory and operational risks. Competition from larger, more established companies in the cannabinoid market poses a threat to APPB's market share and growth prospects. Stringent regulatory requirements for cannabinoid-based products could delay or prevent the commercialization of its products.